Advocacy and Compliance Issues Impacting Dermatology in 2025

Area of Science:

• Medical Science
• Pathology
• Dermatology

Background:

• Reimbursement denials for immunohistochemistry (IHC) stains have posed challenges in dermatology and dermatopathology.
• Advocacy and policy updates are crucial for maintaining diagnostic service accessibility.

Purpose of the Study:

• To review recent successes in reversing IHC stain reimbursement denials.
• To inform stakeholders about updated regulatory requirements and legislative efforts impacting dermatopathology.

Main Methods:

• Review of recent advocacy outcomes in dermatology and dermatopathology.
• Analysis of new position statements on IHC utilization.
• Explanation of modifications to Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) requirements.
• Outline of legislative initiatives for physician payment reform.

Main Results:

• Successful reversal of prior IHC stain reimbursement denials through advocacy.
• Publication of a new position statement guiding IHC utilization.
• Implementation of updated CLIA and CAP laboratory director requirements.
• Advancement of legislative initiatives supporting federal payment reform for physicians.

Conclusions:

• Collective advocacy efforts can effectively address and reverse reimbursement challenges.
• Adherence to updated regulatory standards and engagement in legislative processes are vital for the field.
• Continued focus on physician payment reform is essential for the sustainability of specialized diagnostic services.